Emerging thrombotic effects of drug eluting stents

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):261-2. doi: 10.1161/01.ATV.0000255308.41576.ae.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Cell Proliferation / drug effects
  • Coronary Restenosis / prevention & control
  • Coronary Stenosis / therapy
  • Coronary Thrombosis / etiology*
  • Coronary Thrombosis / genetics
  • Coronary Thrombosis / metabolism
  • Coronary Thrombosis / physiopathology*
  • Drug Delivery Systems
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology*
  • Humans
  • Mice
  • Mice, Transgenic
  • Paclitaxel / administration & dosage
  • Paclitaxel / pharmacology
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Risk Factors
  • Sirolimus / administration & dosage
  • Sirolimus / pharmacology
  • Stents / adverse effects*
  • Tissue Plasminogen Activator / genetics
  • Tissue Plasminogen Activator / metabolism
  • Up-Regulation / genetics

Substances

  • Antineoplastic Agents
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Tissue Plasminogen Activator
  • Paclitaxel
  • Sirolimus